You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
|
|---|---|
| Published in |
Frontiers in Medicine, April 2018
|
| DOI | 10.3389/fmed.2018.00049 |
| Pubmed ID | |
| Authors |
Florence Roufosse |
| Abstract |
Improved understanding of the contribution of eosinophils to various chronic inflammatory conditions, most notably allergic asthma, has encouraged development of monoclonal antibodies specifically targeting mediators and surface receptors involved in eosinophil expansion and activation. The pivotal role of interleukin-5 (IL-5) in eosinophil biology, its high specificity for this leukocyte subset, and its involvement in the majority of eosinophilic conditions make it a very enticing target for treatment of eosinophil-mediated disorders. Two types of antibodies have been developed to target eosinophils: antibodies against IL-5 (mepolizumab and reslizumab), and an antibody against the IL-5-receptor-alpha-chain (IL-5Rα) (benralizumab). Both types of antibodies prevent IL-5 from engaging its receptor and in addition, anti-IL-5Rα antibodies induce target-cell lysis. They have been shown to reduce circulating eosinophil counts rapidly in humans with various disorders. Herein, a brief overview of the role of IL-5 in eosinophil biology will be presented, followed by a description of the development and characteristics of antibodies targeting IL-5 or its receptor. Results of clinical trials evaluating the efficacy and safety of these new antibodies in diseases (other than eosinophilic asthma) with prominent tissue eosinophilia are reviewed, followed by safety considerations and potential future applications. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Switzerland | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 156 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 31 | 20% |
| Student > Ph. D. Student | 19 | 12% |
| Other | 12 | 8% |
| Student > Master | 12 | 8% |
| Student > Bachelor | 11 | 7% |
| Other | 28 | 18% |
| Unknown | 43 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 30% |
| Immunology and Microbiology | 19 | 12% |
| Biochemistry, Genetics and Molecular Biology | 12 | 8% |
| Agricultural and Biological Sciences | 7 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Other | 12 | 8% |
| Unknown | 52 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 May 2022.
All research outputs
#6,499,267
of 23,041,514 outputs
Outputs from Frontiers in Medicine
#1,471
of 5,806 outputs
Outputs of similar age
#115,256
of 329,530 outputs
Outputs of similar age from Frontiers in Medicine
#35
of 107 outputs
Altmetric has tracked 23,041,514 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 5,806 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.3. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,530 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.